ABILIFY 15 MG TABLET
FDA nonproprietary name: aripiprazole
For 30 tablets
Pharmacies pay
$559.56 filed
30 × $18.65186 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$675.80 filed
30 × $22.52657 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.2× estimated
Medicare paid 1.2× what pharmacies pay.
Part D averages every strength and form sold under “Abilify” / “Aripiprazole” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$648.49 estimated
$559.56 + $83.93 (15%) + $5.00 fee per fill = $648.49
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ABILIFY 15 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as aripiprazole, under the trade name “ABILIFY”.
FDA gives its dosage form as tablet and its route as oral.
The labeler, the company named on the label, is Otsuka America Pharmaceutical, Inc.
FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 59148-0009-13.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $559.56 for 30 tablets (30 × $18.65186 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $0.13123 per EA filed.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What NADAC measures · Why 30 tablets · NADAC explanation codes
The NDC
- 59148-0009-13 · Otsuka America Pharmaceutical, Inc. · $18.65186 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
20 other products in the NADAC file share the FDA nonproprietary name aripiprazole with ABILIFY 15 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| ABILIFY 2 MG TABLET | $18.65546 per EA filed | $22.52657 per EA filed |
| ABILIFY 5 MG TABLET | $18.6836 per EA filed | $22.52657 per EA filed |
| ABILIFY 10 MG TABLET | $18.61552 per EA filed | $22.52657 per EA filed |
| ABILIFY 15 MG TABLET this page | $18.65186 per EA filed | $22.52657 per EA filed |
| ABILIFY 20 MG TABLET | $26.25042 per EA filed | $22.52657 per EA filed |
| ABILIFY 30 MG TABLET | $26.23171 per EA filed | $22.52657 per EA filed |
| ABILIFY ASIMTUFII 720 MG/2.4 ML | $1,785.22689 per ML filed | $1,764.23642 per ML filed |
| ABILIFY ASIMTUFII 960 MG/3.2 ML | $1,782.92743 per ML filed | $1,764.23642 per ML filed |
| ABILIFY MAINTENA ER 300 MG SYR | $2,139.08683 per EA filed | $2,236.80 per EA derived |
| ABILIFY MAINTENA ER 300 MG VL | $2,141.14811 per EA filed | $2,236.80 per EA derived |
| ABILIFY MAINTENA ER 400 MG SYR | $2,853.24574 per EA filed | $2,982.40 per EA derived |
| ABILIFY MAINTENA ER 400 MG VL | $2,857.76593 per EA filed | $2,982.40 per EA derived |
| ARIPIPRAZOLE 1 MG/ML SOLUTION | $0.33119 per ML filed | We don’t know yet |
| ARIPIPRAZOLE 2 MG TABLET | $0.11462 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE 5 MG TABLET | $0.10973 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE 10 MG TABLET | $0.11173 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE 15 MG TABLET | $0.13123 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE 20 MG TABLET | $0.17429 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE 30 MG TABLET | $0.17347 per EA filed | $1.54994 per EA filed |
| ARIPIPRAZOLE ODT 10 MG TABLET | $2.47005 per EA filed | $15.55143 per EA filed |
| ARIPIPRAZOLE ODT 15 MG TABLET | $2.22394 per EA filed | $15.55143 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
Compared with its class
Its NADAC price is $18.65186 per EA filed.
Of the 130 other products in FDA’s Atypical Antipsychotic class priced per EA, 48 have a higher middle NADAC price and 82 a lower one. The one in the middle is OLANZAPINE-FLUOXETINE 6-25 MG, at $4.05968 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $675.80 for 30 tablets, at an average of $22.52657 per EA in 2024 (2024-01-01 to 2024-12-31) for “Abilify” and “Aripiprazole”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 7,139 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: ARIPIPRAZOLE 15 MG TABLET. Ask your pharmacist or prescriber; do not switch on your own.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ABILIFY 15 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Abilify / Aripiprazole: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
Related pages
Its pharmacologic class
Related in the same class
- QUETIAPINE FUMARATE 100 MG TAB
- OLANZAPINE 10 MG TABLET
- RISPERIDONE 0.25 MG TABLET
- CLOZAPINE 100 MG TABLET
- LURASIDONE HCL 120 MG TABLET